From Simply Wall St Knight Therapeutics (TSX:GUD)
Simply Wall St Growth Rating:
Overview: Knight Therapeutics Inc. develops, manufactures, acquires, licenses, markets, and distributes pharmaceutical and consumer health products as well as medical devices worldwide with a market cap of CA$570.85 million.
Operations: Revenue from pharmaceuticals amounted to CA$337.87 million.
Insider Ownership: 22.3%
Knight Therapeutics has substantial insider ownership, indicating strong internal confidence. Despite a recent net loss of CAD 1.94 million for Q2 2024, the company raised its annual revenue guidance to between CAD 355 million and CAD 365 million. The stock trades significantly below its estimated fair value, suggesting potential upside. Knight is also actively repurchasing shares, having bought back over 6 million shares recently, which may positively impact shareholder value in the long term.